CML
MCID: LKM063
MIFTS: 72

Leukemia, Chronic Myeloid (CML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Myeloid

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid 56 52 73 13 37
Chronic Myelogenous Leukemia 12 74 52 25 58 73 17
Chronic Myeloid Leukemia 12 52 25 58 36 42 15
Cml 56 12 52 25 58 73
Chronic Granulocytic Leukemia 12 52 25 58
Leukemia, Philadelphia Chromosome-Positive, Resistant to Imatinib 56 6
Chronic Myeloid Leukaemia 12 15
Myeloid Leukemia, Chronic 12 71
Leukemia, Chronic Myeloid, Philadelphia Chromosome Positive, Somatic 56
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 71
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 73
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive 43
Leukemia, Chronic Myeloid, Atypical 73
Cml - Chronic Myelogenous Leukemia 12
Chronic Granulocytic Leukaemia 12
Leukemia, Chronic Myelogenous 56
Chronic Myelogenous Leukaemia 12
Chronic Myelocytic Leukemia 25
Leukemia, Myeloid, Chronic 39
Myeloid Leukemia Chronic 54
Acml 73
Cgl 25

Characteristics:

Orphanet epidemiological data:

58
chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
leukemia, chronic myeloid:
Inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8552
OMIM 56 608232
KEGG 36 H00004
ICD9CM 34 205.1
MeSH 43 D015464
NCIt 49 C3174
SNOMED-CT 67 63364005 92818009
ICD10 32 C92.2
ICD10 via Orphanet 33 C92.1
UMLS via Orphanet 72 C0023473
Orphanet 58 ORPHA521
UMLS 71 C0023473 C1292772

Summaries for Leukemia, Chronic Myeloid

Genetics Home Reference : 25 Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets. Chronic myeloid leukemia usually begins after age 60. Common features include excessive tiredness (fatigue), fever, and weight loss. Many affected individuals develop an enlarged spleen (splenomegaly), which can cause a feeling of fullness in the abdomen and a loss of appetite. About half of people with chronic myeloid leukemia do not initially have any signs and symptoms and are diagnosed when a blood test is performed for another reason. The condition consists of three phases: the chronic phase, the accelerated phase, and the blast phase (or blast crisis). In the chronic phase, the number of mature white blood cells is elevated, and myeloblasts account for less than 10 percent of blood cells. Signs and symptoms of the condition during this phase are typically mild or absent and worsen slowly. The chronic phase can last from months to years. In the accelerated phase, the number of myeloblasts is slightly higher, making up 10 to 29 percent of blood cells. The signs and symptoms continue to worsen. The accelerated phase usually lasts 4 to 6 months, although it is skipped in some affected individuals. In blast crisis, 30 percent or more of blood or bone marrow cells are myeloblasts. Signs and symptoms are most severe in this phase, including a massively enlarged spleen, bone pain, and weight loss. Serious infections and uncontrolled bleeding can be life-threatening.

MalaCards based summary : Leukemia, Chronic Myeloid, also known as chronic myelogenous leukemia, is related to philadelphia-negative chronic myeloid leukemia and atypical chronic myeloid leukemia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Leukemia, Chronic Myeloid is ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase), and among its related pathways/superpathways are Chronic myeloid leukemia and Endometrial cancer. The drugs Thiotepa and Cefepime have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are myeloproliferative disorder and splenomegaly

Disease Ontology : 12 A myeloid leukemia that is characterized by over production of white blood cells.

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 521 Definition Chronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases. Epidemiology Its annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000. Clinical description The disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly. Etiology CML is characterised by the presence of the Philadelphia chromosome , an abnormality resulting from a balanced translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)). This translocation generates a BCR/ABL gene fusion encoding a constitutively active tyrosine kinase. CML does not appear to be an inherited disease and the factors leading to predisposition for the disorder remain largely unknown. Management and treatment Although an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001. Visit the Orphanet disease page for more resources.

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include: Fatigue Weight loss Night sweats Fever Pain or a feeling of fullness below the ribs on the left side Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

KEGG : 36 Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of a pluripotent stem cell. The natural history of CML has a triphasic clinical course comprising of an initial chronic phase (CP), which is characterized by expansion of functionally normal myeloid cells, followed by an accelerated phase (AP) and finally a more aggressive blast phase (BP), with loss of terminal differentiation capacity. On the cellular level, CML is associated with a specific chromosome abnormality, the t(9; 22) reciprocal translocation that forms the Philadelphia (Ph) chromosome. The Ph chromosome is the result of a molecular rearrangement between the c-ABL proto-oncogene on chromosome 9 and the BCR (breakpoint cluster region) gene on chromosome 22. The BCR/ABL fusion gene encodes p210 BCR/ABL, an oncoprotein, which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity and is predominantly localized in the cytoplasm. While fusion of c-ABL and BCR is believed to be the primary cause of the chronic phase of CML, progression to blast crisis requires other molecular changes. Common secondary abnormalities include mutations in TP53, RB, and p16/INK4A, or overexpression of genes such as EVI1. Additional chromosome translocations are also observed,such as t(3;21)(q26;q22), which generates AML1-EVI1.

UniProtKB/Swiss-Prot : 73 Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts.
Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Wikipedia : 74 Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white... more...

More information from OMIM: 608232

Related Diseases for Leukemia, Chronic Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 903, show less)
# Related Disease Score Top Affiliating Genes
1 philadelphia-negative chronic myeloid leukemia 35.2 BCR ABL1
2 atypical chronic myeloid leukemia 34.9 SETBP1 RUNX1 JAK2 ABL1
3 leukemia 34.5 RUNX1 NRAS KIT JAK2 HOTAIR BCR
4 polycythemia vera 34.2 KIT JAK2 IFNA1 H19 ABL1
5 juvenile myelomonocytic leukemia 34.0 SETBP1 RUNX1 NRAS JAK2
6 myelodysplastic/myeloproliferative neoplasm 33.9 SETBP1 NRAS KIT JAK2 ABL1
7 myeloid leukemia 33.2 RUNX1 NRAS KIT JAK2 BCR ABL1
8 myelofibrosis 32.9 SETBP1 RUNX1 MIR223 MEG3 KIT JAK2
9 myeloma, multiple 32.7 UCA1 NRAS MIR17 MEG3 KIT JAK2
10 essential thrombocythemia 32.5 MIR223 KIT JAK2 IFNA1 BCR ABL1
11 hematologic cancer 32.5 RUNX1 MIR223 MIR20A MIR17 MIR10A KIT
12 myeloproliferative neoplasm 32.4 RUNX1 NRAS MIR20A MIR17 MIR10A KIT
13 chronic leukemia 32.3 SETBP1 KIT JAK2 BCR ABL1
14 sarcoma 32.3 NRAS KIT JAK2 IFNA1 HOTAIR CRKL
15 leukemia, acute myeloid 32.3 UCA1 SETBP1 RUNX1 NRAS MIR223 MIR17
16 b-cell lymphoma 32.2 MIR20A MIR17 JAK2 HOTAIR BCR
17 gastrointestinal stromal tumor 32.2 KIT JAK2 HOTAIR BCR ABL1
18 gastric cancer 32.1 UCA1 NRAS MIR223 MIR20A MIR203A MIR17
19 bladder cancer 32.1 UCA1 NRAS MIR223 MIR203A MIR17 MIR10A
20 diffuse large b-cell lymphoma 32.0 MIR17 MIR10A JAK2 HULC HOTAIR
21 colorectal cancer 31.9 UCA1 NRAS MIR223 MIR20A MIR203A MIR17
22 acute leukemia 31.9 SETBP1 RUNX1 KIT JAK2 BCR
23 pancreatic cancer 31.9 UCA1 MIR223 MIR20A MIR203A MIR17 MIR10A
24 leukemia, chronic lymphocytic 31.9 NRAS MIR223 MIR20A MIR17 KIT JAK2
25 lymphoma, non-hodgkin, familial 31.9 NRAS MIR20A MIR17 JAK2 BCR
26 hepatocellular carcinoma 31.8 UCA1 NRAS MIR223 MIR20A MIR203A MIR17
27 renal cell carcinoma, nonpapillary 31.8 UCA1 NRAS MIR17 MIR10A KIT IFNA1
28 prostate cancer 31.7 UCA1 MIR223 MIR20A MIR203A MIR17 MIR10A
29 systemic mastocytosis 31.7 NRAS KIT JAK2 IFNA1
30 nasopharyngeal carcinoma 31.7 NRAS MIR17 MEG3 HULC HOTAIR H19
31 mastocytosis 31.7 KIT JAK2 IFNA1
32 leukemia, acute lymphoblastic 3 31.7 RUNX1 BCR ABL1
33 leukemia, acute lymphoblastic 31.7 RUNX1 MIR223 MIR203A MIR17 KIT JAK2
34 kidney cancer 31.7 MIR20A MIR17 MEG3 IFNA1 HOTAIR H19
35 thyroid cancer, nonmedullary, 1 31.7 MEG3 HULC HOTAIR H19
36 myelodysplastic syndrome 31.6 SETBP1 RUNX1 NRAS MIR10A MEG3 KIT
37 chronic myelomonocytic leukemia 31.6 SETBP1 RUNX1 NRAS KIT JAK2
38 ovarian cancer 31.6 UCA1 MIR223 MIR17 MEG3 KIT JAK2
39 childhood leukemia 31.5 RUNX1 BCR ABL1
40 cervical cancer 31.5 UCA1 MIR20A MIR17 MEG3 HULC HOTAIR
41 hypereosinophilic syndrome 31.5 KIT JAK2 IFNA1 ABL1
42 medulloblastoma 31.5 NRAS MIR20A MIR17 KIT JAK2 HOTAIR
43 thyroid gland cancer 31.4 UCA1 NRAS MIR17 KIT HOTAIR H19
44 splenomegaly 31.4 SETBP1 JAK2 IFNA1
45 lung cancer susceptibility 3 31.4 NRAS MIR17 MEG3 KIT HOTAIR H19
46 liver cirrhosis 31.4 MEG3 IFNA1 HULC HOTAIR
47 esophageal cancer 31.4 UCA1 MIR223 MIR203A MEG3 HULC HOTAIR
48 aggressive systemic mastocytosis 31.4 RUNX1 KIT IFNA1 H19
49 childhood acute myeloid leukemia 31.3 SETBP1 NRAS KIT
50 chronic neutrophilic leukemia 31.3 SETBP1 JAK2 IFNA1 ABL1
51 osteogenic sarcoma 31.3 UCA1 MEG3 HULC HOTAIR H19
52 chronic eosinophilic leukemia 31.3 KIT JAK2 IFNA1 ABL1
53 blood platelet disease 31.3 RUNX1 KIT JAK2 IFNA1
54 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.2 RUNX1 KIT
55 neuroblastoma 31.2 NRAS MIR17 MEG3 KIT HOTAIR H19
56 acute promyelocytic leukemia 31.2 RUNX1 NRAS MIR223 IFNA1 CRKL
57 central nervous system disease 31.1 MIR223 MIR17 MIR10A H19
58 nervous system disease 31.1 MIR223 MIR20A MIR17 MIR10A
59 cryoglobulinemia, familial mixed 31.0 IFNA1 BCR
60 congenital generalized lipodystrophy 11.7
61 pdgfrb-associated chronic eosinophilic leukemia 11.6
62 myelocytic leukemia-like syndrome, familial, chronic 11.4
63 melanoma 11.3 UCA1 NRAS MIR17 MEG3 KIT IFNA1
64 lipodystrophy, congenital generalized, type 2 11.2
65 lipodystrophy, congenital generalized, type 1 11.2
66 oral squamous cell carcinoma 11.2 UCA1 MIR223 MIR203A MIR17 MIR10A MEG3
67 glioma 11.2 UCA1 MIR20A MIR17 MEG3 HULC HOTAIR
68 prostate disease 11.1 MIR223 MIR20A MIR17 MEG3 H19
69 pancreatic ductal adenocarcinoma 11.1 UCA1 MIR223 MIR203A HOTAIR H19
70 gastrointestinal system cancer 11.1 MIR223 MIR20A MIR17 HOTAIR H19
71 core binding factor acute myeloid leukemia 11.0 RUNX1 NRAS KIT JAK2
72 bladder urothelial carcinoma 11.0 UCA1 NRAS MEG3 KIT HOTAIR
73 gastric cardia adenocarcinoma 11.0 MIR203A MEG3 HOTAIR H19
74 leukocyte disease 11.0 MIR17 KIT JAK2 IFNA1
75 bone marrow cancer 11.0 MIR17 KIT JAK2 ABL1
76 integumentary system disease 11.0 NRAS MIR17 KIT IFNA1
77 pituitary adenoma 11.0 MIR223 MEG3 HOTAIR H19
78 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 11.0 KIT JAK2 ABL1
79 glioma susceptibility 1 11.0 NRAS MEG3 HOTAIR H19
80 acquired metabolic disease 11.0 MIR223 MIR20A MIR17 MIR10A
81 cebpa-associated familial acute myeloid leukemia 11.0 RUNX1 KIT JAK2
82 malignant glioma 11.0 MEG3 HULC HOTAIR H19
83 8p11 myeloproliferative syndrome 11.0 RUNX1 KIT BCR
84 neutrophilia, hereditary 11.0 SETBP1 MIR223 JAK2
85 vulvar disease 11.0 NRAS MIR223 KIT
86 immune system disease 11.0 MIR223 MIR20A MIR17 MIR10A
87 mucosal melanoma 10.9 NRAS KIT IFNA1
88 respiratory system disease 10.9 MIR223 MIR20A MIR17 MIR10A
89 graft-versus-host disease 10.9
90 blood coagulation disease 10.9 KIT JAK2 IFNA1
91 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.9 JAK2 ABL1
92 gallbladder cancer 10.9 UCA1 MEG3 HOTAIR H19
93 intestinal benign neoplasm 10.9 MIR20A MIR17 MIR10A
94 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.9 RUNX1 KIT
95 malignant anus melanoma 10.9 NRAS KIT
96 malignant dermis tumor 10.9 NRAS KIT
97 malignant skin fibrous histiocytoma 10.9 NRAS KIT
98 vulvar melanoma 10.8 NRAS KIT
99 gastrointestinal system benign neoplasm 10.8 MIR20A MIR17 MIR10A
100 mental retardation, autosomal dominant 29 10.8 SETBP1 ABL1
101 functionless pituitary adenoma 10.7 MEG3 HOTAIR
102 lymphoblastic leukemia, acute, with lymphomatous features 10.7 JAK2 ABL1
103 sm-ahnmd 10.7 KIT JAK2
104 acquired polycythemia 10.7 JAK2 ABL1
105 b-cell adult acute lymphocytic leukemia 10.7 BCR ABL1
106 sezary's disease 10.7 MIR223 MIR17 IFNA1
107 exanthem 10.7
108 myelophthisic anemia 10.6 JAK2 ABL1
109 chronic graft versus host disease 10.5
110 severe combined immunodeficiency 10.5
111 polycythemia 10.5
112 chromosome 22q11.2 deletion syndrome, distal 10.5 CRKL BCR
113 deficiency anemia 10.5
114 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.5
115 spindle cell sarcoma 10.5
116 pancytopenia 10.4
117 thyroid gland anaplastic carcinoma 10.4 NRAS MIR17 KIT
118 withdrawal disorder 10.4
119 mucositis 10.4
120 cytokine deficiency 10.4
121 lymphoma, hodgkin, classic 10.3
122 bilirubin metabolic disorder 10.3
123 pik3ca-related overgrowth syndrome 10.3
124 dowling-degos disease 1 10.3
125 hemolytic anemia 10.3
126 pericarditis 10.3
127 lysosomal storage disease 10.3
128 autoimmune disease 10.2
129 retinoblastoma 10.2
130 anemia, autoimmune hemolytic 10.2
131 aspergillosis 10.2
132 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
133 hypophosphatemia 10.2
134 nephrotic syndrome 10.2
135 purpura 10.2
136 familial retinoblastoma 10.2
137 neutrophilic dermatosis, acute febrile 10.2
138 colitis 10.2
139 lymphoblastic lymphoma 10.2
140 disseminated intravascular coagulation 10.2
141 hypothyroidism 10.2
142 kidney disease 10.2
143 alopecia 10.2
144 homologous wasting disease 10.2
145 hypertriglyceridemia, familial 10.2
146 bronchiolitis obliterans 10.2
147 bronchiolitis 10.2
148 breast cancer 10.2
149 pulmonary hypertension, primary, 1 10.2
150 branchiootic syndrome 1 10.2
151 microvascular complications of diabetes 5 10.2
152 lung disease, immunodeficiency, and chromosome breakage syndrome 10.2
153 peripheral vascular disease 10.2
154 hypopyon 10.2
155 respiratory failure 10.2
156 allergic hypersensitivity disease 10.2
157 pulmonary alveolar proteinosis 10.2
158 uveitis 10.2
159 diarrhea 10.2
160 polyneuropathy 10.2
161 vascular disease 10.2
162 calcinosis 10.2
163 viral hepatitis 10.2
164 hepatitis b 10.2
165 iron metabolism disease 10.2
166 pustulosis of palm and sole 10.2
167 psoriasis 10.2
168 avascular necrosis 10.2
169 erythroleukemia, familial 10.1
170 myasthenia gravis 10.1
171 sickle cell anemia 10.1
172 follicular lymphoma 10.1
173 hemopericardium 10.1
174 pericardial effusion 10.1
175 telangiectasis 10.1
176 pure red-cell aplasia 10.1
177 optic nerve disease 10.1
178 thrombocytosis 10.1
179 herpes zoster 10.1
180 vasculitis 10.1
181 granulocytopenia 10.1
182 thrombasthenia 10.1
183 complex chromosomal rearrangement 10.1
184 red cell aplasia 10.1
185 thyroid carcinoma 10.1
186 neurofibromatosis, type i 10.1
187 langerhans cell histiocytosis 10.1
188 hypogonadotropic hypogonadism 10.1
189 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 10.1
190 mucopolysaccharidosis-plus syndrome 10.1
191 varicose veins 10.1
192 endosteal hyperostosis, autosomal dominant 10.1
193 spondyloarthropathy 1 10.1
194 hypercholesterolemia, familial, 1 10.1
195 li-fraumeni syndrome 10.1
196 retinal detachment 10.1
197 sarcoidosis 1 10.1
198 immune deficiency disease 10.1
199 thymoma, familial 10.1
200 body mass index quantitative trait locus 1 10.1
201 li-fraumeni syndrome 2 10.1
202 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
203 peripheral artery disease 10.1
204 covid-19 10.1
205 nasopharyngitis 10.1
206 hydrocephalus 10.1
207 cardiac tamponade 10.1
208 portal vein thrombosis 10.1
209 iron deficiency anemia 10.1
210 inflammatory spondylopathy 10.1
211 gout 10.1
212 cystitis 10.1
213 retinal vein occlusion 10.1
214 autoimmune hepatitis 10.1
215 central retinal vein occlusion 10.1
216 dermatitis 10.1
217 hairy cell leukemia 10.1
218 adenocarcinoma 10.1
219 acute kidney failure 10.1
220 lipid metabolism disorder 10.1
221 thymoma 10.1
222 skin disease 10.1
223 systemic scleroderma 10.1
224 hyperglycemia 10.1
225 myopathy 10.1
226 infertility 10.1
227 lymphopenia 10.1
228 connective tissue disease 10.1
229 spondylitis 10.1
230 compartment syndrome 10.1
231 chronic kidney disease 10.1
232 sideroblastic anemia 10.1
233 intracranial hypertension 10.1
234 meningitis 10.1
235 stomatitis 10.1
236 miliary tuberculosis 10.1
237 toxoplasmosis 10.1
238 acute myeloblastic leukemia with maturation 10.1
239 acute non lymphoblastic leukemia 10.1
240 bone marrow necrosis 10.1
241 polymyositis 10.1
242 syncope 10.1
243 tremor 10.1
244 acute liver failure 10.1
245 polyploidy 10.1
246 overgrowth syndrome 10.1
247 pfeiffer syndrome 10.0
248 behcet syndrome 10.0
249 leukemia, acute monocytic 10.0
250 cryptogenic organizing pneumonia 10.0
251 bone disease 10.0
252 b-lymphoblastic leukemia/lymphoma 10.0
253 brucellosis 10.0
254 adult-onset still's disease 10.0
255 squamous cell carcinoma 10.0
256 chronic granulomatous disease 10.0
257 progressive multifocal leukoencephalopathy 10.0
258 t-cell lymphoblastic leukemia/lymphoma 10.0
259 lupus erythematosus 10.0
260 acute erythroid leukemia 10.0
261 acute basophilic leukemia 10.0
262 arteries, anomalies of 10.0
263 fibrosis of extraocular muscles, congenital, 1 10.0
264 hypercalcemia, infantile, 1 10.0
265 myositis 10.0
266 pelger-huet anomaly 10.0
267 polykaryocytosis inducer 10.0
268 porphyria cutanea tarda 10.0
269 scleroderma, familial progressive 10.0
270 fanconi anemia, complementation group d2 10.0
271 fanconi anemia, complementation group a 10.0
272 gaucher disease, type i 10.0
273 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
274 scott syndrome 10.0
275 yemenite deaf-blind hypopigmentation syndrome 10.0
276 microvascular complications of diabetes 1 10.0
277 kala-azar 1 10.0
278 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
279 intraocular pressure quantitative trait locus 10.0
280 microvascular complications of diabetes 2 10.0
281 dengue virus 10.0
282 membranous nephropathy 10.0
283 helix syndrome 10.0
284 anaplastic large cell lymphoma 10.0
285 mantle cell lymphoma 10.0
286 hemorrhagic cystitis 10.0
287 lymphoma 10.0
288 thrombosis 10.0
289 hepatic veno-occlusive disease 10.0
290 acquired von willebrand syndrome 10.0
291 sensorineural hearing loss 10.0
292 osteomyelitis 10.0
293 dermatomyositis 10.0
294 thalassemia 10.0
295 portal hypertension 10.0
296 hypospadias 10.0
297 pulmonary edema 10.0
298 infant gynecomastia 10.0
299 optic neuritis 10.0
300 vogt-koyanagi-harada disease 10.0
301 von willebrand's disease 10.0
302 hemolytic-uremic syndrome 10.0
303 gynecomastia 10.0
304 focal segmental glomerulosclerosis 10.0
305 porphyria 10.0
306 osteopetrosis 10.0
307 hyperparathyroidism 10.0
308 cholestasis 10.0
309 multiple cranial nerve palsy 10.0
310 toxic shock syndrome 10.0
311 gonadal dysgenesis 10.0
312 thrombocytopenia due to platelet alloimmunization 10.0
313 thrombocytopenia 10.0
314 neovascular glaucoma 10.0
315 neuritis 10.0
316 impotence 10.0
317 hyperuricemia 10.0
318 hypogonadism 10.0
319 gaucher's disease 10.0
320 constipation 10.0
321 colon adenocarcinoma 10.0
322 macrocytic anemia 10.0
323 splenic infarction 10.0
324 acute pancreatitis 10.0
325 cryoglobulinemia 10.0
326 papillary carcinoma 10.0
327 ischemia 10.0
328 turner syndrome 10.0
329 gastric adenocarcinoma 10.0
330 plasmacytoma 10.0
331 pyoderma 10.0
332 hypokalemia 10.0
333 pancreatitis 10.0
334 adult acute lymphocytic leukemia 10.0
335 acquired immunodeficiency syndrome 10.0
336 thyroiditis 10.0
337 end stage renal disease 10.0
338 hyperthyroidism 10.0
339 cataract 10.0
340 mucormycosis 10.0
341 monocytic leukemia 10.0
342 pyoderma gangrenosum 10.0
343 herpes simplex 10.0
344 pyomyositis 10.0
345 leishmaniasis 10.0
346 macroglobulinemia 10.0
347 visceral leishmaniasis 10.0
348 exophthalmos 10.0
349 hemophilia 10.0
350 ltbp4-related cutis laxa 10.0
351 sickle cell disease 10.0
352 frontal fibrosing alopecia 10.0
353 lymphosarcoma 10.0
354 pseudo pelger-huet anomaly 10.0
355 raynaud phenomenon 10.0
356 headache 10.0
357 low-flow priapism 10.0
358 acute generalized exanthematous pustulosis 10.0
359 thrombotic microangiopathy 10.0
360 precursor t-cell acute lymphoblastic leukemia 10.0
361 pituitary adenoma, prolactin-secreting 10.0
362 gallbladder disease 1 10.0
363 metabolic acidosis 10.0
364 ileitis 10.0
365 metal allergy 10.0
366 pituitary apoplexy 10.0
367 quadriplegia 10.0
368 acute closed-angle glaucoma 10.0
369 craniopharyngioma 10.0
370 loeffler endocarditis 10.0
371 ovarian cyst 10.0
372 reticulosarcoma 10.0
373 polyarteritis nodosa 10.0
374 microscopic polyangiitis 10.0
375 mycobacterium avium complex infections 10.0
376 trisomy 22 10.0
377 paresthesia 10.0
378 pneumococcal meningitis 10.0
379 annular erythema 9.9
380 cleidocranial dysplasia 9.9
381 3-methylglutaconic aciduria, type iii 9.9
382 pars planitis 9.9
383 psoriatic arthritis 9.9
384 human granulocytic anaplasmosis 9.9
385 neuroretinitis 9.9
386 ehrlichiosis 9.9
387 sialadenitis 9.9
388 primary hyperparathyroidism 9.9
389 splenic sequestration 9.9
390 glossitis 9.9
391 dysostosis 9.9
392 hidradenitis 9.9
393 retinitis 9.9
394 embryoma 9.9
395 rapidly progressive glomerulonephritis 9.9
396 bacterial meningitis 9.9
397 hydrocele 9.9
398 malakoplakia 9.9
399 sudden sensorineural hearing loss 9.9
400 ring chromosome 9.9
401 adams-oliver syndrome 1 9.9
402 neurofibromatosis, type ii 9.9
403 arteriovenous malformations of the brain 9.9
404 fragile site 10q25 9.9
405 lichen sclerosus et atrophicus 9.9
406 alkaline phosphatase, plasma level of, quantitative trait locus 1 9.9
407 williams-beuren syndrome 9.9
408 wilms tumor 1 9.9
409 anemia, hypochromic microcytic, with iron overload 1 9.9
410 takayasu arteritis 9.9
411 enterocolitis 9.9
412 factor v deficiency 9.9
413 intracranial hypertension, idiopathic 9.9
414 familial mediterranean fever 9.9
415 oliver syndrome 9.9
416 stroke, ischemic 9.9
417 wilms tumor 5 9.9
418 dermatitis, atopic 9.9
419 homocysteinemia 9.9
420 pulmonary disease, chronic obstructive 9.9
421 diarrhea 6 9.9
422 human herpesvirus 8 9.9
423 t-cell lymphoma, subcutaneous panniculitis-like 9.9
424 chronic diarrhea due to guanylate cyclase 2c overactivity 9.9
425 hyperphosphatemia 9.9
426 hypochromic microcytic anemia 9.9
427 marginal zone b-cell lymphoma 9.9
428 peripheral t-cell lymphoma 9.9
429 villous adenoma 9.9
430 aphasia 9.9
431 adams-oliver syndrome 9.9
432 erythema elevatum diutinum 9.9
433 hereditary lymphedema i 9.9
434 childhood acute lymphocytic leukemia 9.9
435 nodal marginal zone lymphoma 9.9
436 polycystic kidney disease 9.9
437 viral meningitis 9.9
438 microinvasive gastric cancer 9.9
439 short bowel syndrome 9.9
440 hemiplegia 9.9
441 acquired thrombocytopenia 9.9
442 anhidrosis 9.9
443 pertussis 9.9
444 spondyloarthropathy 9.9
445 microcytic anemia 9.9
446 constrictive pericarditis 9.9
447 horner's syndrome 9.9
448 lyme disease 9.9
449 hemosiderosis 9.9
450 testicular lymphoma 9.9
451 nephrocalcinosis 9.9
452 acute cystitis 9.9
453 skin sarcoidosis 9.9
454 facial paralysis 9.9
455 alcoholic liver cirrhosis 9.9
456 renal tubular acidosis 9.9
457 alcohol use disorder 9.9
458 ichthyosis 9.9
459 hepatitis c 9.9
460 malignant fibrous histiocytoma 9.9
461 hemorrhagic disease 9.9
462 hepatitis 9.9
463 angiodysplasia 9.9
464 orchitis 9.9
465 benign mesothelioma 9.9
466 acute interstitial pneumonia 9.9
467 substance abuse 9.9
468 multiple endocrine neoplasia 9.9
469 proctitis 9.9
470 demyelinating disease 9.9
471 germinoma 9.9
472 breast adenocarcinoma 9.9
473 sagittal sinus thrombosis 9.9
474 plexopathy 9.9
475 granuloma annulare 9.9
476 lynch syndrome 9.9
477 coronary stenosis 9.9
478 folliculitis 9.9
479 fibrous histiocytoma 9.9
480 seminoma 9.9
481 macular retinal edema 9.9
482 immune-complex glomerulonephritis 9.9
483 peripheral nervous system disease 9.9
484 cll/sll 9.9
485 spinal stenosis 9.9
486 langerhans cell sarcoma 9.9
487 pineal region germinoma 9.9
488 active peptic ulcer disease 9.9
489 peritonitis 9.9
490 chronic monocytic leukemia 9.9
491 bacterial pneumonia 9.9
492 megakaryocytic leukemia 9.9
493 amyloidosis 9.9
494 diabetes mellitus 9.9
495 epididymo-orchitis 9.9
496 diabetes insipidus 9.9
497 smoldering myeloma 9.9
498 hemorrhoid 9.9
499 tuberculous peritonitis 9.9
500 irf6-related disorders 9.9
501 amyloidosis aa 9.9
502 chromosome 17p deletion 9.9
503 chromosome 20q deletion 9.9
504 chromosome 9 inversion 9.9
505 chromosome 9q duplication 9.9
506 diffuse cutaneous systemic sclerosis 9.9
507 growth hormone deficiency 9.9
508 ichthyosis, acquired 9.9
509 leukemia, t-cell, chronic 9.9
510 lymphoma aids related 9.9
511 mosaic trisomy 8 9.9
512 muscular dystrophy white matter spongiosis 9.9
513 mycobacterium kansasii 9.9
514 pyogenic granuloma 9.9
515 testicular seminoma 9.9
516 tuberculous meningitis 9.9
517 postherpetic neuralgia 9.9
518 refractory anemia with excess blasts in transformation 9.9
519 rare hemorrhagic disorder 9.9
520 partial deletion of chromosome 7 9.9
521 rare hereditary hemochromatosis 9.9
522 osteonecrosis of the jaw 9.9
523 acute monoblastic/monocytic leukemia 9.9
524 bullous pyoderma gangrenosum 9.9
525 legg-calve-perthes disease 9.9
526 platelet membrane fluidity 9.9
527 pulmonary venoocclusive disease 1, autosomal dominant 9.9
528 fabry disease 9.9
529 ventricular fibrillation, paroxysmal familial, 1 9.9
530 hepatitis c virus 9.9
531 thrombocytopenia 5 9.9
532 brachydactyly 9.9
533 cutaneous t cell lymphoma 9.9
534 inguinal hernia 9.9
535 diphtheria 9.9
536 hepatitis a 9.9
537 blastomycosis 9.9
538 pseudobulbar palsy 9.9
539 dilated cardiomyopathy 9.9
540 pyuria 9.9
541 hereditary angioedema 9.9
542 cholera 9.9
543 heart septal defect 9.9
544 atrial heart septal defect 9.9
545 basal cell carcinoma 9.9
546 skin atrophy 9.9
547 pulmonary venoocclusive disease 9.9
548 gastrointestinal system disease 9.9
549 molluscum contagiosum 9.9
550 gas gangrene 9.9
551 irritable bowel syndrome 9.9
552 familial monosomy 7 syndrome 9.9
553 banti's syndrome 9.9
554 wells syndrome 9.9
555 extrapontine myelinolysis 9.9
556 monosomy 21 9.9
557 toxic oil syndrome 9.9
558 eosinophilic colitis 9.9
559 storage pool platelet disease 9.9
560 subacute thyroiditis 9.9
561 mycobacterium malmoense 9.9
562 cafe-au-lait spots, multiple 9.8
563 gray platelet syndrome 9.8
564 nondisjunction 9.8
565 cyclic neutropenia 9.8
566 pernicious anemia 9.8
567 myeloperoxidase deficiency 9.8
568 sea-blue histiocyte disease 9.8
569 pleurisy 9.8
570 gastric ulcer 9.8
571 megacolon 9.8
572 dysentery 9.8
573 shigellosis 9.8
574 subleukemic leukemia 9.8
575 azoospermia 9.8
576 toxic megacolon 9.8
577 nocardiosis 9.8
578 anuria 9.8
579 subacute leukemia 9.8
580 histiocytosis 9.8
581 thyroid gland follicular carcinoma 9.8
582 hypertrichosis 9.8
583 lymph node tuberculosis 9.8
584 aleukemic leukemia cutis 9.8
585 hemangioendothelioma 9.8
586 mycobacterium fortuitum 9.8
587 nodular regenerative hyperplasia 9.8
588 achondroplasia 9.8
589 amyotrophic lateral sclerosis 1 9.8
590 atrial standstill 1 9.8
591 burkitt lymphoma 9.8
592 hashimoto thyroiditis 9.8
593 immunoglobulin switch sequences 9.8
594 inclusion body myositis 9.8
595 kaposi sarcoma 9.8
596 systemic lupus erythematosus 9.8
597 mastocytosis, cutaneous 9.8
598 osteoporosis 9.8
599 paroxysmal extreme pain disorder 9.8
600 parkinson disease, late-onset 9.8
601 pneumothorax, primary spontaneous 9.8
602 sister chromatid exchange, frequency of 9.8
603 small cell cancer of the lung 9.8
604 smith-magenis syndrome 9.8
605 chromosome 2q35 duplication syndrome 9.8
606 thrombocytopenic purpura, autoimmune 9.8
607 thrombophilia due to thrombin defect 9.8
608 triiodothyronine receptor auxiliary protein 9.8
609 down syndrome 9.8
610 vitiligo-associated multiple autoimmune disease susceptibility 6 9.8
611 ataxia-telangiectasia 9.8
612 celiac disease 1 9.8
613 epidermodysplasia verruciformis 1 9.8
614 bernard-soulier syndrome 9.8
615 leprosy 3 9.8
616 microcephaly 1, primary, autosomal recessive 9.8
617 mycosis fungoides 9.8
618 ocular motor apraxia 9.8
619 reticulum cell sarcoma 9.8
620 schinzel-giedion midface retraction syndrome 9.8
621 glanzmann thrombasthenia 9.8
622 graves disease 1 9.8
623 werner syndrome 9.8
624 xeroderma pigmentosum, complementation group d 9.8
625 xeroderma pigmentosum, variant type 9.8
626 body mass index quantitative trait locus 11 9.8
627 wiskott-aldrich syndrome 9.8
628 hemophilia b 9.8
629 ataxia and polyneuropathy, adult-onset 9.8
630 kearns-sayre syndrome 9.8
631 retinitis pigmentosa 11 9.8
632 helicobacter pylori infection 9.8
633 budd-chiari syndrome 9.8
634 body mass index quantitative trait locus 9 9.8
635 body mass index quantitative trait locus 8 9.8
636 meningioma, radiation-induced 9.8
637 vitiligo-associated multiple autoimmune disease susceptibility 1 9.8
638 bone mineral density quantitative trait locus 3 9.8
639 meningioma, familial 9.8
640 body mass index quantitative trait locus 4 9.8
641 body mass index quantitative trait locus 10 9.8
642 hypereosinophilic syndrome, idiopathic 9.8
643 anxiety 9.8
644 body mass index quantitative trait locus 7 9.8
645 myocardial infarction 9.8
646 severe cutaneous adverse reaction 9.8
647 aplastic anemia 9.8
648 rhabdoid tumor predisposition syndrome 1 9.8
649 bone mineral density quantitative trait locus 8 9.8
650 thrombocytopenia 4 9.8
651 colorectal cancer 3 9.8
652 body mass index quantitative trait locus 12 9.8
653 body mass index quantitative trait locus 14 9.8
654 bone mineral density quantitative trait locus 15 9.8
655 cyanosis, transient neonatal 9.8
656 beta-thalassemia 9.8
657 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
658 body mass index quantitative trait locus 18 9.8
659 pachyonychia congenita 3 9.8
660 thrombocytopenia 6 9.8
661 body mass index quantitative trait locus 19 9.8
662 diarrhea 9 9.8
663 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.8
664 body mass index quantitative trait locus 20 9.8
665 pulmonary hypertension 9.8
666 bacterial sepsis 9.8
667 autoimmune glomerulonephritis 9.8
668 erythema multiforme 9.8
669 familial adenomatous polyposis 9.8
670 brugada syndrome 9.8
671 inflammatory bowel disease 9.8
672 severe congenital neutropenia 9.8
673 vitamin b12 deficiency 9.8
674 lymphoplasmacytic lymphoma 9.8
675 secondary progressive multiple sclerosis 9.8
676 fibroma 9.8
677 ductal carcinoma in situ 9.8
678 ptosis 9.8
679 paroxysmal nocturnal hemoglobinuria 9.8
680 cardiac arrest 9.8
681 omphalocele 9.8
682 lymphoproliferative syndrome 9.8
683 salmonellosis 9.8
684 bone resorption disease 9.8
685 fibrous dysplasia 9.8
686 myeloid and lymphoid neoplasms associated with pdgfrb rearrangement 9.8
687 tongue carcinoma 9.8
688 familial episodic pain syndrome 9.8
689 osteonecrosis 9.8
690 endocarditis 9.8
691 bacterial infectious disease 9.8
692 perforated corneal ulcer 9.8
693 tonsillitis 9.8
694 meningoencephalitis 9.8
695 osteomalacia 9.8
696 interstitial nephritis 9.8
697 thrombotic thrombocytopenic purpura 9.8
698 primary polycythemia 9.8
699 lipoid nephrosis 9.8
700 hydronephrosis 9.8
701 arteriovenous malformation 9.8
702 tetanus 9.8
703 spinal meningioma 9.8
704 choroiditis 9.8
705 hypertensive retinopathy 9.8
706 cauda equina syndrome 9.8
707 nephrosclerosis 9.8
708 patau syndrome 9.8
709 panuveitis 9.8
710 lymphocytic choriomeningitis 9.8
711 goiter 9.8
712 common variable immunodeficiency 9.8
713 descending colon cancer 9.8
714 plica syndrome 9.8
715 primary biliary cirrhosis 9.8
716 neutropenia 9.8
717 graves' disease 9.8
718 secondary hyperparathyroidism 9.8
719 acute kidney tubular necrosis 9.8
720 central nervous system leukemia 9.8
721 hereditary spherocytosis 9.8
722 leukostasis 9.8
723 branch retinal artery occlusion 9.8
724 central retinal artery occlusion 9.8
725 megaloblastic anemia 9.8
726 pulmonary sarcoidosis 9.8
727 tuberous sclerosis 9.8
728 squamous cell papilloma 9.8
729 amenorrhea 9.8
730 rubeosis iridis 9.8
731 poems syndrome 9.8
732 papilledema 9.8
733 candidiasis 9.8
734 panniculitis 9.8
735 urticaria 9.8
736 angioedema 9.8
737 renovascular hypertension 9.8
738 lymphadenitis 9.8
739 keratosis 9.8
740 pneumothorax 9.8
741 neuroendocrine tumor 9.8
742 duodenal ulcer 9.8
743 cheilitis 9.8
744 cholecystitis 9.8
745 rectum cancer 9.8
746 rectum adenocarcinoma 9.8
747 ascending colon cancer 9.8
748 transient cerebral ischemia 9.8
749 lateral sclerosis 9.8
750 craniosynostosis 9.8
751 arteriosclerosis 9.8
752 gangliocytoma 9.8
753 acromegaly 9.8
754 gastric antral vascular ectasia 9.8
755 splenic abscess 9.8
756 agammaglobulinemia 9.8
757 papilloma 9.8
758 synovitis 9.8
759 idiopathic interstitial pneumonia 9.8
760 hemoglobinopathy 9.8
761 membranoproliferative glomerulonephritis 9.8
762 glomerulonephritis 9.8
763 severe acute respiratory syndrome 9.8
764 pulmonary tuberculosis 9.8
765 iga glomerulonephritis 9.8
766 testicular cancer 9.8
767 breast sarcoma 9.8
768 glioblastoma multiforme 9.8
769 astrocytoma 9.8
770 gingival overgrowth 9.8
771 keratoacanthoma 9.8
772 teratoma 9.8
773 inappropriate adh syndrome 9.8
774 mammary paget's disease 9.8
775 skin carcinoma 9.8
776 cellulitis 9.8
777 mixed connective tissue disease 9.8
778 cavernous sinus thrombosis 9.8
779 choriocarcinoma 9.8
780 kallmann syndrome 9.8
781 intermittent claudication 9.8
782 pulmonary fibrosis 9.8
783 arthropathy 9.8
784 cranial nerve palsy 9.8
785 thrombophlebitis 9.8
786 gastritis 9.8
787 liver disease 9.8
788 erythrasma 9.8
789 juvenile xanthogranuloma 9.8
790 dysgerminoma 9.8
791 secretory meningioma 9.8
792 lymphoplasmacyte-rich meningioma 9.8
793 bilateral retinoblastoma 9.8
794 uremia 9.8
795 proliferative glomerulonephritis 9.8
796 ganglioneuroma 9.8
797 demyelinating polyneuropathy 9.8
798 intestinal disease 9.8
799 dystonia 9.8
800 pneumonia 9.8
801 t-cell acute lymphoblastic leukemia 9.8
802 hemoglobinuria 9.8
803 nephrolithiasis 9.8
804 congestive heart failure 9.8
805 paraplegia 9.8
806 reactive arthritis 9.8
807 follicular dendritic cell sarcoma 9.8
808 hypersplenism 9.8
809 plasma cell neoplasm 9.8
810 adenoma 9.8
811 cerebrovascular disease 9.8
812 juvenile rheumatoid arthritis 9.8
813 hepatoblastoma 9.8
814 monoclonal gammopathy of uncertain significance 9.8
815 adenomatoid tumor 9.8
816 peptic ulcer disease 9.8
817 situs inversus 9.8
818 retinal telangiectasia 9.8
819 hemarthrosis 9.8
820 scabies 9.8
821 ileus 9.8
822 paralytic ileus 9.8
823 corneal ulcer 9.8
824 retinal artery occlusion 9.8
825 lung disease 9.8
826 ulcerative colitis 9.8
827 measles 9.8
828 chickenpox 9.8
829 myeloid sarcoma 9.8
830 neuropathy 9.8
831 neurofibromatosis 9.8
832 in situ carcinoma 9.8
833 crohn's disease 9.8
834 chorioretinitis 9.8
835 pemphigus 9.8
836 lichen planus 9.8
837 erythromelalgia 9.8
838 priapism 9.8
839 iridocyclitis 9.8
840 acute myocardial infarction 9.8
841 pulmonary embolism 9.8
842 plasma cell leukemia 9.8
843 encephalitis 9.8
844 fasciitis 9.8
845 necrotizing fasciitis 9.8
846 neurofibroma 9.8
847 babesiosis 9.8
848 aphthous stomatitis 9.8
849 renal tuberculosis 9.8
850 mixed phenotype acute leukemia 9.8
851 hemometra 9.8
852 hypoglycemia 9.8
853 47,xyy 9.8
854 48,xyyy 9.8
855 acute graft versus host disease 9.8
856 acute monoblastic leukemia 9.8
857 candida glabrata 9.8
858 carcinoma showing thymus-like differentiation 9.8
859 chromosomal triplication 9.8
860 chromosome 9q deletion 9.8
861 dextrocardia with situs inversus 9.8
862 drug reaction with eosinophilia and systemic symptoms 9.8
863 dwarfism 9.8
864 exfoliative dermatitis 9.8
865 germ cells tumors 9.8
866 graham-little-piccardi-lassueur syndrome 9.8
867 hansen's disease 9.8
868 lymphangiectasis 9.8
869 mosaic trisomy 9 9.8
870 oral cancer 9.8
871 spinal shock 9.8
872 tetraploidy 9.8
873 tetrasomy 21 9.8
874 therapy related acute myeloid leukemia and myelodysplastic syndrome 9.8
875 triploidy 9.8
876 aneurysm 9.8
877 back pain 9.8
878 cytomegalovirus infection 9.8
879 dysphagia 9.8
880 encephalopathy 9.8
881 foot drop 9.8
882 hypoxia 9.8
883 posttransplant acute limbic encephalitis 9.8
884 cerebrofacial arteriovenous metameric syndrome 9.8
885 rapidly involuting congenital hemangioma 9.8
886 trisomy 1q 9.8
887 virus-associated trichodysplasia spinulosa 9.8
888 primary cutaneous anaplastic large cell lymphoma 9.8
889 alk-positive anaplastic large cell lymphoma 9.8
890 acute myeloid leukemia with t(6;9)(p23;q34) 9.8
891 secondary pulmonary alveolar proteinosis 9.8
892 erythema multiforme major 9.8
893 benign idiopathic neonatal seizures 9.8
894 argyria 9.8
895 acute mast cell leukemia 9.8
896 premature aging 9.8
897 hypopigmentation of the skin 9.8
898 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 9.8
899 rare tumor 9.8
900 monosomy 22 9.8
901 refractory anemia 9.8
902 systemic mastocytosis with associated hematologic neoplasm 9.8
903 streptococcal toxic-shock syndrome 9.8

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN): (showing 3, show less)


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:



Diseases related to Leukemia, Chronic Myeloid

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

Human phenotypes related to Leukemia, Chronic Myeloid:

58 31 (showing 15, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myeloproliferative disorder 58 31 obligate (100%) Obligate (100%) HP:0005547
2 splenomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0001744
3 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
4 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
5 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
6 leukocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0001974
7 poor appetite 58 31 frequent (33%) Frequent (79-30%) HP:0004396
8 thrombocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0001894
9 abnormal basophil morphology 31 frequent (33%) HP:0001912
10 chronic myelogenous leukemia 31 HP:0005506
11 abnormality of blood and blood-forming tissues 58 Frequent (79-30%)
12 abnormality of granulocytes 58 Frequent (79-30%)
13 abnormality of basophils 58 Frequent (79-30%)
14 reduced leukocyte alkaline phosphatase 31 HP:0004852
15 ph-positive acute lymphoblastic leukemia 31 HP:0004848

Symptoms via clinical synopsis from OMIM:

56
Hematology:
chronic myelogenous leukemia
ph-positive acute lymphoblastic leukemia

Laboratory Abnormalities:
low leukocyte alkaline phosphatase activity
presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease

Clinical features from OMIM:

608232

UMLS symptoms related to Leukemia, Chronic Myeloid:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.17 ABL1 BCR CRKL JAK2 KIT NRAS

Drugs & Therapeutics for Leukemia, Chronic Myeloid

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 420, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
5
Ofloxacin Approved Phase 3 82419-36-1 4583
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
8
Panobinostat Approved, Investigational Phase 2, Phase 3 404950-80-7 6918837
9
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
10
Morphine Approved, Investigational Phase 3 57-27-2 5288826
11
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
14 Orange Approved Phase 2, Phase 3
15
Mercaptopurine Approved Phase 3 50-44-2 667490
16
Acyclovir Approved Phase 3 59277-89-3 2022
17
Thioguanine Approved Phase 3 154-42-7 2723601
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
20
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
21
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
22
Dalteparin Approved Phase 3 9005-49-6
23
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
24
Captopril Approved Phase 3 62571-86-2 44093
25
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
26
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
27
Ribavirin Approved Phase 3 36791-04-5 37542
28
Palivizumab Approved, Investigational Phase 3 188039-54-5
29
Tazobactam Approved Phase 3 89786-04-9 123630
30
Vancomycin Approved Phase 3 1404-90-6 14969 441141
31
Piperacillin Approved Phase 3 66258-76-2 43672
32
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
33
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
34
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
35
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
36
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
37
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
38
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
39
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
40
Polyestradiol phosphate Approved Phase 3 28014-46-2
41
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
42
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
43 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
44 Anesthetics, Dissociative Phase 3
45 Dextrans Phase 2, Phase 3
46 Anti-Anxiety Agents Phase 3
47 Antipsychotic Agents Phase 3
48 Respiratory System Agents Phase 3
49 Antiprotozoal Agents Phase 3
50 Antiparasitic Agents Phase 3